Ruxolitinib, sold under the brand name Jakafi among others, is a medication used for the treatment of intermediate or high-risk myelofibrosis, a type...
26 KB (2,153 words) - 06:52, 20 October 2024
Administration (FDA) approved ruxolitinib (Jakafi) as a treatment for intermediate or high-risk myelofibrosis. Ruxolitinib serves as an inhibitor of JAK...
27 KB (2,844 words) - 13:15, 3 August 2024
Food and Drug Administration (FDA) approved the first JAK inhibitor, ruxolitinib, to treat a skin condition. Some JAK1 inhibitors are based on a benzimidazole...
37 KB (3,296 words) - 05:23, 19 October 2024
"Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)" at ClinicalTrials.gov Clinical trial number NCT04057573 for "Topical Ruxolitinib Evaluation...
42 KB (4,420 words) - 06:35, 20 October 2024
disease. Many clinical trials are ongoing involving JAK inhibitors such as ruxolitinib and tofacitinib. Alopecia areata Alopecia totalis "Alopecia universalis...
11 KB (1,130 words) - 10:21, 11 October 2024
pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix), Opzelura (Ruxolitinib), Tabrecta (capmatinib), Olumiant...
11 KB (763 words) - 23:44, 7 October 2024
arthritis, psoriatic arthritis, and ulcerative colitis; fedratinib, and ruxolitinib. The substance is quickly absorbed from the gut with an absolute bioavailability...
43 KB (3,613 words) - 02:13, 16 July 2024
patients to near-normal life expectancy. Recently, a JAK2 inhibitor, namely ruxolitinib, has been approved for use in primary myelofibrosis. Trials of these...
16 KB (1,524 words) - 20:11, 12 February 2024
published in tandem with a phase II clinical trial showing the same for ruxolitinib. In a June 2015 case report, a 53-year-old woman with vitiligo showed...
35 KB (3,270 words) - 15:33, 10 October 2024
agent) or anagrelide (Agrylin). In Janus kinase 2 positive disorders, ruxolitinib (Jakafi) can be effective.[citation needed] Kumar PJ, Clark ML (2005)...
11 KB (1,066 words) - 01:55, 17 March 2024
are used in the treatment of seborrheic dermatitis. In September 2021, ruxolitinib cream (Opzelura) was approved by the U.S. Food and Drug Administration...
68 KB (6,964 words) - 13:08, 22 September 2024
additional treatment option for those with certain genetic markers. Ruxolitinib (brand name Jakafi), a Janus kinase 2 (JAK2) inhibitor, is also used...
24 KB (2,684 words) - 10:59, 5 June 2024
antifungal treatments, and immunosuppression. The JAK-STAT inhibitor ruxolitinib is being investigated as a treatment specifically for its normalizing...
14 KB (1,157 words) - 23:43, 9 June 2024
Metandienone Nemolizumab Oclacitinib Oxymetazoline Povidone-iodine Pregnenolone acetate Progestogens (e.g., progesterone) Ruxolitinib Tiratricol Tralokinumab...
92 KB (9,247 words) - 03:39, 15 October 2024
Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod AZD-1480 Baricitinib...
35 KB (3,965 words) - 16:19, 27 September 2024
Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod AZD-1480 Baricitinib...
32 KB (3,478 words) - 07:51, 20 October 2024
Metandienone Nemolizumab Oclacitinib Oxymetazoline Povidone-iodine Pregnenolone acetate Progestogens (e.g., progesterone) Ruxolitinib Tiratricol Tralokinumab...
22 KB (2,243 words) - 21:48, 21 September 2024
Metandienone Nemolizumab Oclacitinib Oxymetazoline Povidone-iodine Pregnenolone acetate Progestogens (e.g., progesterone) Ruxolitinib Tiratricol Tralokinumab...
202 KB (20,190 words) - 09:03, 20 October 2024
medications are being studied. In 2014, preliminary findings showing that oral ruxolitinib, a drug approved by the US Food and Drug Administration (FDA) for bone...
43 KB (4,303 words) - 02:14, 9 September 2024
Metandienone Nemolizumab Oclacitinib Oxymetazoline Povidone-iodine Pregnenolone acetate Progestogens (e.g., progesterone) Ruxolitinib Tiratricol Tralokinumab...
47 KB (4,450 words) - 10:55, 12 October 2024
Metandienone Nemolizumab Oclacitinib Oxymetazoline Povidone-iodine Pregnenolone acetate Progestogens (e.g., progesterone) Ruxolitinib Tiratricol Tralokinumab...
14 KB (1,261 words) - 15:48, 8 October 2024
Metandienone Nemolizumab Oclacitinib Oxymetazoline Povidone-iodine Pregnenolone acetate Progestogens (e.g., progesterone) Ruxolitinib Tiratricol Tralokinumab...
3 KB (215 words) - 23:23, 12 June 2024
Metandienone Nemolizumab Oclacitinib Oxymetazoline Povidone-iodine Pregnenolone acetate Progestogens (e.g., progesterone) Ruxolitinib Tiratricol Tralokinumab...
43 KB (4,357 words) - 08:11, 15 July 2024
Metandienone Nemolizumab Oclacitinib Oxymetazoline Povidone-iodine Pregnenolone acetate Progestogens (e.g., progesterone) Ruxolitinib Tiratricol Tralokinumab...
34 KB (3,429 words) - 20:54, 5 September 2024
Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod AZD-1480 Baricitinib...
33 KB (3,686 words) - 07:30, 20 May 2024
scabies. Its mechanism of action remains unknown. JAK inhibitors, such as ruxolitinib topical cream; see topical JAK inhibitor Local anesthetics, such as benzocaine...
34 KB (3,721 words) - 04:21, 28 August 2024
Metandienone Nemolizumab Oclacitinib Oxymetazoline Povidone-iodine Pregnenolone acetate Progestogens (e.g., progesterone) Ruxolitinib Tiratricol Tralokinumab...
79 KB (7,699 words) - 17:51, 9 October 2024
Metandienone Nemolizumab Oclacitinib Oxymetazoline Povidone-iodine Pregnenolone acetate Progestogens (e.g., progesterone) Ruxolitinib Tiratricol Tralokinumab...
22 KB (1,812 words) - 09:08, 9 October 2024
Metandienone Nemolizumab Oclacitinib Oxymetazoline Povidone-iodine Pregnenolone acetate Progestogens (e.g., progesterone) Ruxolitinib Tiratricol Tralokinumab...
27 KB (2,274 words) - 02:54, 22 March 2024
disease. However, the first generation of these drugs, tofacitinib and ruxolitinib, lacked subtype selectivity, affecting JAK1/JAK3 and JAK1/JAK2 respectively...
46 KB (4,534 words) - 22:58, 20 August 2024